Enrofloxacin EP Impurity B

High performance liquid chromatography determination of prulifloxacin and five related impurities in pharmaceutical formulations
Marcello Locatelli ∗, Federica De Lutiis, Giuseppe Carlucci
Journal of Pharmaceutical and Biomedical Analysis 78–79 (2013) 27–33
 
A Validated Stability-Indicating HPLC Method for Simultaneous Determination of Amoxicillin and Enrofloxacin Combination in an Injectable Suspension
Nidal Batrawi 1 , Shorouq Wahdan 1 and Fuad Al-Rimawi
Sci Pharm. 2017; 85(1): 6.
 
Stability-Indicating RP-HPLC Method for Simultaneous Estimation of Enrofloxacin and Its Degradation Products in Tablet Dosage Forms
V. Ashok Chakravarthy,1 B. B. V. Sailaja,1 and Avvaru Praveen Kumar
Hindawi Publishing Corporation Journal of Analytical Methods in Chemistry Volume 2015, Article ID 735145, 11 pages
 
Evaluation of the Presence and Levels of Enrofloxacin, Ciprofloxacin, Sulfaquinoxaline and Oxytetracycline in Broiler Chickens after Drug Administration
Débora Cristina Sampaio de Assis, Guilherme Resende da Silva,Isabela Pereira Lanza, Ana Cláudia dos Santos Rossi Ribeiro, Ângela Maria Quintão Lana, Leonardo José Camargos Lara, Tadeu Chaves de Figueiredo and Silvana de Vasconcelos Cançado
PLoS One. 2016; 11(11):

Enrofloxacin EP Impurity B is chemically 1-Cyclopropyl-6-fluoro-4-oxo-7-(piperazin-1-yl)-1,4-dihydroquinoline-3-carboxylic acid. Enrofloxacin EP Impurity B is supplied with detailed characterization data compliant with regulatory guideline. Enrofloxacin EP Impurity B can be used for the analytical method development, method validation (AMV), Quality Controlled (QC) application for Abbreviated New Drug Application (ANDA) or during commercial production of Enrofloxacin.

The product can be used as reference standards and further traceability against pharmacopeial standards (USP or EP) can be provided based on feasibility. SynZeal products are for analytical purpose only and not for human use.